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KEY POINTS
 Chronic granulomatous disease (CGD) is a single gene defect that can be reconstituted
in vitro and does not require complete correction to be effective, as proven by the normal
lives of many X-linked carriers, and by the stable chimeras generated in some transplant
protocols.
 Unlike the case with severe combined immunodeficiency, corrected CGD cells do not
have a growth or survival advantage in the marrow or tissue. Therefore, selection and
augmentation of those cells is difficult.
 Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is active outside the
neutrophil, such as in nuclear factor kb signaling, liver damage from carcinogens, and
the arterial vasculature.
 NADPH oxidase somatic and hematopoietic activity is involved in strokes and pulmonary
vascular permeability. NADPH contributes to long-term potentiation of memory and may
be related to IQ.
 NADPH oxidase is clearly active in many more sites than just phagocytes, suggesting that
CGD is more complex and can teach about more than just infections and bone marrow
transplants alone.Chronic granulomatous disease (CGD) was first described in 19541 and 19572 as
recurrent infections occurring in the setting of hypergammaglobulinemia, as opposed
to the disease then recently recognized by Bruton,3 in which infections were associ-
ated with hypogammaglobulinemia. The disease was not well characterized until
1959,4 when it was initially termed fatal granulomatous disease of childhood, but it
is now simply referred to as chronic granulomatous disease. Originally thought to be
only an X-linked disease, its recognition in girls in 1968 also led to the determination
of autosomal recessive forms.5 Over almost 60 years, CGD has evolved from a disease
of early fatality to one of effective management with high survival.6 CGD is a paradigmThis work supported by the Division of Intramural Research, National Institute of Allergy and
Infectious Diseases, National Institutes of Health.
Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, CRC B3-4141, MSC 1684, Bethesda, MD 20892-1684, USA
E-mail address: smh@nih.gov
Hematol Oncol Clin N Am 27 (2013) 89–99
http://dx.doi.org/10.1016/j.hoc.2012.11.002 hemonc.theclinics.com
0889-8588/13/$ – see front matter Published by Elsevier Inc.
Holland90for nonlymphoid primary immune defects, and has guided elucidation of oxygen
metabolism in the phagocyte, vasculature, and brain.7 It has been in the forefront of
the development of antimicrobial prophylaxis before the advent of advanced HIV
and before its routine use in neutropenia.8 It has been an attractive target for gene
therapy and bone marrow transplantation for nonmalignant diseases. Therefore,
CGD is worthy of attention for its historical interest and because it is a disease for
which expert management is imperative.
Multiple separate proteins contribute to the intact nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase, mutations in 5 of which lead to the single syndrome of
CGD. NADPH oxidase catalyzes the transfer of an electron from cytoplasmic NADPH
to molecular oxygen (6; OMIM# 306400, 233690, 233700, 233710, 601488), thereby
oxidizing NADPH and leading to the name NADPH oxidase. Although impairments of
theNADPH oxidase typically present as phagocyte defects, in fact only gp91phox is rela-
tively phagocyte-specific,whereas theother autosomal componentsare alsoexpressed
elsewhere.7 The components are broken into membrane-bound (cytochrome b558,
composed of gp91phox and p22phox) and cytosolic (p47phox, p67phox, and p40phox) struc-
tures. The subunits gp91phox andp22phox require eachother for expression in thephago-
cyte; however, because p22phox is expressed in other tissues and gp91phox is not,
p22phox and the other members of the NADPH oxidase join with other partners in the
other tissues, which are other members of theNox family of proteins. Therefore, individ-
uals who have autosomal recessive forms of CGDmayalso have other subtle abnormal-
ities, such as vascular disease and diabetes in p47phox-deficient CGD or perhaps
inflammatory bowel disease in p40phox-deficient CGD.9
Activation of the NADPH oxidase is a carefully choreographed process.6 On cellular
activation, such as ingestion of bacteria of fungi, the cytosolic components p47phox
and p67phox are phosphorylated and bind tightly together. The secondary (specific)
granules, which contain the cytochrome complex (gp91phox and p22phox) fuse with
the phagolysosome, followed by the primary (azurophilic) granules, which contain
the antibacterial peptides neutrophil elastase and cathepsin G. This process embeds
the cytochrome in the wall of the phagolysosome and the antibacterial peptides inside
it. The cytoplasmic complex of p47phox and p67phox in association with p40phox and
RAC2 combine with the cytochrome to form the intact NADPH oxidase, which is
oriented into the internal aspect of the phagolysosome (this process can also occur
on the plasma membrane focused outside the cell). An electron is then taken from
cytoplasmic NADPH and donated to molecular oxygen inside the phagolysosome,
leading to the formation of superoxide. In the presence of superoxide dismutase,
this is converted to hydrogen peroxide, which, in the presence of myeloperoxidase
and chlorine in the phagolysosome, is converted to bleach. Although the metabolites
of superoxide themselves can contribute to bacterial killing, the generation of super-
oxide has broader implications.10 With the generation of superoxide, a charge is
imparted to the phagolysosome that is rectified by the rapid influx of potassium
ions.11 This potassium influx leads to activation of the now-intraphagosomal peptides,
which mediate microbial killing.10,11 Therefore, reactive oxidants are working more as
intracellular signaling molecules, leading to activation of other nonoxidative pathways
in addition to causing killing directly. Thus, a spectrum of microbicidal activity can be
regulated by NADPH oxidase activity, rather than distinct oxidative and nonoxidative
pathways and mechanisms.
In addition to activation of intracellular antimicrobial peptides, the NADPH oxidase is
required to activate neutrophil extracellular traps (NETs), complex assemblies of DNA
and antimicrobial peptides released from apoptotic neutrophils.12 Repair of the
NADPH oxidase system with gene therapy in a patient with X-linked CGD led to
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dependent on NADPH function.13
Mutations in all of the 5 structural genes of the NADPH oxidase have been found to
cause CGD. Mutations in gp91phox account for approximately 65% of cases, muta-
tions in p47phox account for approximately 25%, and the remainder are divided
between p67phox and p22phox 6,14; one case of p40phox deficiency has been reported.9
No autosomal dominant cases of CGD have been reported. A large voluntary retro-
spective study in the United States and Europe suggested rates of CGD of around
1 in 200,000 to 1 in 250,000 live births.14,15 Rates in other countries vary depending
on the ethnic practices and degrees of intermarriage: Sweden 1 in 450,000; Japan 1
in 300,000; Israeli Jews 1 in 218,000; Israeli Arabs 1 in 111,000.16 However, the relative
rates of X-linked compared with recessive CGD are distinct. In many countries with
high rates of consanguineous marriage, recessive CGD rates exceed X-linked
rates.15,16 Clinically, X-linked gp91phox-deficient CGD is more severe with earlier
presentation and diagnosis, and more severe infections and earlier death than the
p47phox-deficient form.14,15
Mechanistically, the level of residual superoxide production determines survival, at
least in X-linked CGD.17 The rates of long-term survival are higher in those patients
with X-linked CGD with higher residual superoxide production and lower in those
with lower production. Molecularly, this is caused by the ability of the mutant protein
to support superoxide production. Thus, mutations that lead to no protein production
(nonsense mutations, deletions, certain splice defects) support no residual superoxide
production and have the lowest level of survival. In contrast, those mutations that
permit protein production and superoxide generation (missense mutations before
amino acid 310 except histidine 222) are associated with higher survival rates.
However, mutations at or beyond amino acid 310 are unable to support superoxide
production, presumably because of the strict structural requirements of the intracel-
lular domain of gp91phox for the binding of NADPH and flavin adenine dinucleotide
(FAD).17
Infections of the lung, skin, lymph nodes, and liver are the most frequent first mani-
festations of CGD.6,15 In North America, most infections in CGD are from Staphylo-
coccus aureus, Burkholderia cepacia complex, Serratia marcescens, Nocardia spp,
and Aspergillus spp.6 In other parts of the world Salmonella, Bacille Calmette–Gue´rin
(BCG), and tuberculosis are also important.15,16 Patients with CGD tend to develop
severe localized BCG rather than disseminated BCGosis. Trimethoprim/sulfamethox-
azole prophylaxis has reduced the frequency of bacterial infections in general and
staphylococcal infections in particular. On prophylaxis, staphylococcal infections
are essentially confined to the liver and cervical lymph nodes.6 Staphylococcal liver
abscesses encountered in CGD are dense, caseous, and difficult to drain, and previ-
ously required surgery in almost all cases.18 However, recent studies have shown
that the combination of corticosteroids and antibiotics alone are highly effective in
CGD liver abscesses, allowing cure of liver abscesses without surgery.19,20 Until
recently fungal infections, typically because of Aspergillus spp, were the leading
cause of mortality in CGD.14,15 The advent of highly active antifungal therapy with
the orally active azole antifungals itraconazole, voriconazole, and posaconazole
has changed the face of fungal infections in CGD. Mortality from A fumigatus infec-
tion in CGD is now uncommon, and therefore mortality overall is diminished.21
However, the non-fumigatus Aspergillus spp, and some species of fungi other than
Aspergillus remain difficult to treat and important contributors to mortality.22,23
Overall survival in CGD is now thought to be approximately 90%, stretching well into
adulthood.24 Patients diagnosed before the advent of antifungal azole agents had
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some series.14,15 Since the introduction of itraconazole in the late 1990s, its proof in
antifungal prophylaxis in 2003,25 and the introduction of more active antifungals and
antibacterials, mortality in CGD has plunged.24,26 Access to expert care is clearly
important, as shown by a Japanese study with a 90% survival rate for patients fol-
lowed up at single center.27 Similarly, Mouy and colleagues28 found an 8-year survival
rate of 70.5% for children born before 1978 but a 92.9% survival rate for those born
later. Before the introduction of oral antifungals Winkelstein and colleagues14 reported
X-linked CGD mortality of approximately 5% per year, compared with 2% per year for
the autosomal recessive varieties. van den Berg and colleagues15 found a 23%
mortality in X-linked CGD and a 15% rate of mortality in autosomal recessive CGD
over almost 50 years of European survey. Therefore, overall mortality from infection
in CGD has been significant but will continue to improve with better therapies.
The morbidity of recurrent infections and inflammation, with their associated
end-organ damage and their impact on the child and family, is a major issue. Several
large studies found similar rates of infection of around 0.3 per year.24,26 That is, most
patients are still experiencing at least one severe infection every 3 to 4 years, whether
bacterial or fungal. The persistence of this rate may reflect a minimum inescapable
environmental exposure, or the complexity of maintaining long-term prophylaxis
over a lifetime with a disease that is only intermittently reinforced.
CGD is remarkable because of its very narrow but profound spectrum of infection
susceptibility. B cepacia complex organisms are common causes of pneumonia
and, infrequently, sepsis.29 The closely related B gladioli has also been described in
CGD.30 Chromobacterium violaceum is found in brackish waters, such as those
around the Gulf of Mexico in the United States, and causes sepsis in CGD.31 Franci-
sella philomiragia causes sepsis in CGD and is also found in brackish waters, such as
the Chesapeake Bay, Long Island Sound, and around Nova Scotia.32 Granulibacter
bethesdensis is a novel gram-negative rod that causes chronic necrotizing lymphad-
enitis and can cause sepsis in CGD.33 It can have latent and active phases, similar to
tuberculosis, and has been identified in the United States, Panama, and Spain, sug-
gesting wide distribution. Although the rate of seropositivity for this organism is
approximately 50% in patients with CGD, most of whom have not had recognized
infections, this rate is around 25% in patients without CGD, suggesting broad expo-
sure and the possibility of a clinical syndrome yet to be identified.34
Fungal infections are critically important to recognize in CGD. Several are character-
istic of CGD and virtually never encountered in other diseases: A nidulans, Paecilomy-
ces variotii and P lilacinus, and Neosartorya udagawae. These organisms are highly
pathogenic in those infected with CGD but not in any other patient group, including
transplant recipients.35 In contrast to these filamentous molds that are virtually patho-
gnomonic for CGD, the endemic dimorphic mold infections histoplasmosis, blastomy-
cosis, and coccidioidomycosis do not occur in CGD, nor does cryptococcosis.
Mucormycosis occurs in CGD but only in the setting of significant immunosuppres-
sion.36 The molecular identification of infection should be vigorously pursued in
patients with CGD, especially for fungal infections, because the identification of
a non-fumigatus Aspergillus infection should prompt early consideration of therapeutic
surgery.37
Fungal elements elicit an exuberant inflammatory response in CGD regardless of
whether they are live or dead.38 Mulch pneumonitis refers to acute inhalational expo-
sure to aerosolized decayed organic matter, such asmulch, hay, or dead leaves.39 The
clinical presentation is stereotypic and dramatic: a previously well child or adult
spreads mulch, turns compost, or clears moldy leaves, inhaling numerous fungal
Chronic Granulomatous Disease 93spores and hyphae; 1 to 10 days later a syndrome similar to hypersensitivity pneumo-
nitis begins with fever and dyspnea; chest radiographs show diffuse interstitial
infiltrates; bronchoscopy is usually uninformative but may yield Aspergillus; lung
biopsy shows acute inflammation with necrotizing granulomata and fungi. The most
successful treatments of this syndrome have been with simultaneous antifungals for
the infection and steroids for the inflammation.39 The authors typically institute mero-
penem, voriconazole, and prednisone for this syndrome, because steroids seem to be
crucial for reducing inflammation and allowing independent ventilation. This syndrome
should be considered in all cases of Aspergillus pneumonitis, especially with acute
onset and hypoxia, and therefore implies CGD as the underlying diagnosis. This
syndrome occurs in patients with known CGD but also may be the presentation for
disease, even in adults.
Inflammation in CGD is most prominent in the gastrointestinal and genitourinary
tracts. Esophageal, jejunal, ileal, cecal, rectal, and perirectal involvement with granu-
lomata mimicking Crohn disease have been described.40,41 Functional gastric outlet
obstruction may be the initial presentation of CGD. In a large survey of patients with
CGD followed at the National Institutes of Health, 43% of those with X-linked CGD
had symptomatic, biopsy-proven inflammatory bowel disease (IBD), compared with
only 11% of p47phox-deficient patients.40 However, growth rates were equally dimin-
ished to less than the mean in IBD-affected and unaffected patients. Whether the mild
growth retardation seen in most patients with CGD was from IBD in all cases, or from
some other CGD-associated feature of the disease is unknown, because biopsies
were only performed in symptomatic patients. Growth and growth rates in CGD recov-
ered after bone marrow transplantation, regardless of antecedent IBD.42 Although IBD
may involve any part of the gastrointestinal tract in patients with CGD, perirectal
disease is especially common.41
Treatment of CGD IBD is often long-term and difficult, and the disease is prone to
relapse. Steroids are effective but may cause growth retardation, osteoporosis, and
infection risk. However, at the doses typically used in CGD for maintenance, infections
are rarely an issue. In contrast, although tumor necrosis factor (TNF)-a–blocking agents
are highly effective and rapidly suppress bowel symptoms, they confer a high risk of
infection and death and should be carefully avoided in patients with CGD.43 TNF-a
inhibitors predispose to characteristic CGD pathogens, only more severe episodes.
The authors’ current practice is to initiate therapy for proven IBD in CGD with predni-
sone at 1 mg/kg/d for 1 to 2 weeks and then slowly taper to 0.1 to 0.25 mg/kg/d over
1 to 2 months. Sometimes prednisone can be stopped in children, but the relapse
rate is very high, and re-treatment typically requires reinitiation of the higher dose.
Therefore, after the first recurrence or relapse the authors usually add an antimetabo-
lite, such as azathioprine (Imuran), along with salicylic acid derivatives. Local treat-
ments such as steroid enemas and rectal creams are also highly effective.
Liver involvement in CGD is pronounced and important. Liver abscesses occur in
approximately 35% of patients and until recently have been difficult to treat without
surgery.18 With surgery, cure of liver abscess is common, but unfortunately so is rein-
fection, typically with a different organism from the previous one. Whether certain
patients with CGD are simply predisposed to liver abscesses or having had a previous
liver abscess alters hepatic architecture and blood flow in a way that makes subse-
quent infection more likely remains unclear. High rates of portal venopathy and
nodular regenerative hyperplasia may contribute to portal hypertension, spleno-
megaly, and splenic sequestration.44 This latter point is noteworthy, because the
decline in platelet count is linked to splenomegaly and is also a strong predictor of
mortality in CGD.45 Chronic drug effects, liver enzyme elevations, and recurrent
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tion for recurrent liver abscesses is partly caused by surgery, with its hepatic scarring
and altered blood flow, is unclear. However, avoiding surgery when possible seems
prudent, and the recent demonstration of the effectiveness of steroids and antibiotics
alone in the resolution of liver abscess offers an alternative treatment.20
Genitourinary manifestations of CGD are also common and include bladder granu-
lomata, ureteral obstruction, and urinary tract infection, typically in those with gp91phox
and p22phox deficiencies.46 Eosinophilic cystitis has also been described in CGD.47
Genitourinary complications are also highly steroid responsive. Inflammatory masses
in CGD can mimic tumors and should be considered.48
The diagnosis of CGD is usually made by direct measurement of superoxide
production, ferricytochrome c reduction, chemiluminescence, nitroblue tetrazolium
(NBT) reduction, or dihydrorhodamine oxidation (DHR). DHR is preferable because
of its relative ease of use, its ability to distinguish X-linked from autosomal patterns
of CGD on flow cytometry, its sensitivity to even very low numbers of functional
neutrophils, and its utility in predicting the residual superoxide activity of the patient’s
neutrophils.17,49 The 2 conditions known to give a falsely abnormal DHR are myeloper-
oxidase deficiency50 and SAPHO syndrome.51 In myeloperoxidase deficiency, the
DHR tracing can look like that of X-linked CGD, whereas the NBT and ferricytochrome
c results are normal. This finding is attributed to intracellular (DHR) compared with
extracellular (NBT) superoxide release and dye activation. Glucose 6-phosphate dehy-
drogenase (G6PD) deficiency may also lead to a decreased respiratory burst and
increased susceptibility to bacterial infections.52 However, G6PD deficiency is most
often associated with some degree of hemolytic anemia, whereas CGD is not.
Female carriers of X-linked CGD have 2 populations of phagocytes: 1 that produces
superoxide and 1 that does not, yielding a characteristic mosaic pattern on oxidative
testing. Infections are infrequent unless the normal neutrophils are less than 10%, and
even then are uncommon. However, cases of severe skewing of X-chromosome inac-
tivation have been reported, in which women have virtually no detectable normal cells;
these carriers are at risk for CGD-type infections.53 Reports suggest that the balance
of wild-type to mutant cells may vary over time in the same woman, but this has not
been rigorously proven, as likely as it may seem.53 Discoid lupus erythematosus–
like lesions, aphthous ulcers, and photosensitive rashes have been seen in gp91phox
carriers. Similarly, screening of patients with discoid lupus erythematosus detected
a significant number of previously unsuspected CGD carriers.54–56
Immunoblot and flow cytometry can be used to infer the specific genotype, but
molecular determination of specific mutations is necessary for prenatal diagnosis. A
robust genotype/phenotype correlation has been shown for mutations that permit
residual superoxide production compared with those that do not.17 Male sex, earlier
age at presentation, and increased severity of disease suggest X-linked disease, but
these are only rough guides. The precise gene defect should probably be determined
in all cases, because it is a strong predictor of survival. Autosomal recessive p47phox-
deficient CGD has a significantly better prognosis than X-linked disease.14,15,17
Effective management of CGD is predicated on prophylactic antibiotics and antifun-
gals and interferon (IFN)-g, along with management of acute infections as they occur.
Prophylactic trimethoprim/sulfamethoxazole (5 mg/kg/d trimethoprim divided twice
daily) reduces the frequency of major infections from approximately once every year
to once every 3.5 years, reducing staphylococcal and skin infections without
increasing in the frequency of serious fungal infections in CGD.57 Itraconazole prophy-
laxis prevents fungal infections in CGD (100 mg daily for patients aged <13 y or weigh-
ing <50 kg; 200 mg daily for those aged >13 y or weighing >50 kg).25 IFN-gwas shown
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and severity of infections in CGD by 70% compared with placebo regardless of inher-
itance pattern, sex, or use of prophylactic antibiotics.58 Systemic IFN-g also
augmented neutrophil activity against Aspergillus conidia in vitro.59 Furthermore, in
a study of IFN-g in CGD mice, infections were reduced.60 However, a retrospective
Italian study detected no benefit to the addition of IFN-g beyond that attributed to anti-
bacterial and antifungals alone.24 Long-term follow-up of the large prospective trials
suggests sustained benefit.26 The authors use trimethoprim/sulfamethoxazole, itraco-
nazole, and IFN-g (50 mg/m2) in the treatment of CGD.
Bone marrow transplantation can lead to stable remission of CGD. Regimens
ranging from full myeloablation to nonmyeloablative conditioning lead to cure of
CGD.42,61,62 Even in the setting of refractory fungal infection, bone marrow transplan-
tation has been effective.63 Nonmyeloablative transplants in CGD have been more
successful in children than in adults.64 Although bone marrow transplantation is an
attractive option for the definitive cure of CGD, survival without bone marrow trans-
plantation is roughly comparable, but attended by continuing CGD morbidities,
such as bowel disease and mildly reduced growth.
CGD is a group of single gene defects that can be reconstituted in vitro and does not
require complete correction to be effective, as proven by the normal lives of many X-
linked carriers, and by the stable chimeras generated in some transplant protocols.65
Unlike the case with severe combined immunodeficiency, corrected CGD cells do not
have a growth or survival advantage in the marrow or tissue. Therefore, in vivo selec-
tion and augmentation of those cells is difficult.
NADPH oxidase is active outside the neutrophil, such as in nuclear factor kb
signaling, liver damage from carcinogens, and the arterial vasculature.66–68 NADPH
oxidase somatic and hematopoietic activity is involved in strokes and pulmonary
vascular permeability.69 NADPH contributes to long-term potentiation of memory70
and may be related to IQ.71 Therefore, NADPH oxidase is clearly active in many
more sites than just phagocytes, suggesting that CGD is more complex and can teach
about more than just infections and bone marrow transplants alone.REFERENCES
1. Janeway CA, Craig J, Davidson M, et al. Hypergammaglobulinemia associated
with severe, recurrent and chronic non-specific infection. Am J Dis Child 1954;
88:388–92.
2. Berendes H, Bridges RA, Good RA. A fatal granulomatous disease of childhood:
the clinical study of a new syndrome. Minn Med 1957;40:309.
3. Bruton OC. Agammaglobulinemia. Pediatrics 1952;9(6):722–8.
4. Bridges RA, Berendes H, Good RA. A fatal granulomatous disease of childhood.
Am J Dis Child 1959;97:387.
5. Azimi PH, Bodenbender JG, Hintz RL, et al. Chronic granulomatous disease in
three female siblings. JAMA 1968;206:2865–70.
6. Segal BH, Leto TL, Gallin JI, et al. Genetic, biochemical, and clinical features of
chronic granulomatous disease. Medicine (Baltimore) 2000;79:170–200.
7. Ushio-Fukai M. Localizing NADPH oxidase-derived ROS. Sci STKE 2006;349:re8.
8. Freeman AF, Holland SM. Antimicrobial prophylaxis for primary immunodefi-
ciencies. Curr Opin Allergy Clin Immunol 2009;9(6):525–30.
9. Matute JD, Arias AA, Wright NA, et al. A new genetic subgroup of chronic gran-
ulomatous disease with autosomal recessive mutations in p40 phox and selective
defects in neutrophil NADPH oxidase activity. Blood 2009;114(15):3309–15.
Holland9610. Tkalcevic J, Novelli M, Phylactides M, et al. Impaired immunity and enhanced
resistance to endotoxin in the absence of neutrophil elastase and cathepsin G.
Immunity 2000;12(2):201–10.
11. Reeves EP, Lu H, Jacobs HL, et al. Killing activity of neutrophils is mediated
through activation of proteases by K1 flux. Nature 2002;416:291–7.
12. Fuchs TA, Abed U, Goosmann C, et al. Novel cell death program leads to neutro-
phil extracellular traps. J Cell Biol 2007;176(2):231–41.
13. Bianchi M, Hakkim A, Brinkmann V, et al. Restoration of NET formation by gene
therapy in CGD controls aspergillosis. Blood 2009;114(13):2619–22.
14. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous
disease. Report on a national registry of 368 patients. Medicine (Baltimore)
2000;79:155–69.
15. van den Berg JM, van Koppen E, Ahlin A, et al. Chronic granulomatous disease:
the European experience. PLoS One 2009;4(4):e5234. http://dx.doi.org/10.1371/
journal.pone.0005234.
16. Wolach B, Gavrieli R, de Boer M, et al. Chronic granulomatous disease in Israel:
clinical, functional and molecular studies of 38 patients. Clin Immunol 2008;129:
103–14.
17. Kuhns DB, Alvord WG, Heller T, et al. Long term survival and residual NADPH
oxidase function in chronic granulomatous disease. N Engl J Med 2010;
363(27):2600–10.
18. Lublin M, Bartlett DL, Danforth DN, et al. Hepatic abscess in patients with chronic
granulomatous disease. Ann Surg 2002;235:383–91.
19. Yamazaki-Nakashimada MA, Stiehm ER, Pietropaolo-Cienfuegos D, et al. Cortico-
steroid therapy for refractory infections in chronic granulomatous disease: case
reports and review of the literature. Ann Allergy Asthma Immunol 2006;97:
257–61.
20. Leiding JW, Freeman AF, Marciano BE, et al. Corticosteroid therapy for liver
abscess in chronic granulomatous disease. Clin Infect Dis 2011;54:694–700.
21. Blumental S, Mouy R, Mahlaoui N, et al. Invasive mold infections in chronic gran-
ulomatous disease: a 25-year retrospective survey. Clin Infect Dis 2011;53:
e159–69.
22. Vinh DC, Shea YR, Sugui JA, et al. Invasive aspergillosis due to Neosartorya uda-
gawae. Clin Infect Dis 2009;49(1):102–11.
23. Vinh DC, Shea YR, Jones PA, et al. Chronic invasive aspergillosis caused by
Aspergillus viridinutans. Emerg Infect Dis 2009;15(8):1292–4.
24. Martire B, Rondelli R, Soresina A, et al. Clinical features, long-term follow-up and
outcome of a large cohort of patients with Chronic Granulomatous Disease: an
Italian multicenter study. Clin Immunol 2008;126:155–64.
25. Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in
chronic granulomatous disease. N Engl J Med 2003;348:2416–22.
26. Marciano BE, Wesley R, De Carlo ES, et al. Long-term interferon-gamma therapy
for patients with chronic granulomatous disease. Clin Infect Dis 2004;39:692–9.
27. Kobayashi S, Murayama S, Takanashi S, et al. Clinical features and prognoses of
23 patients with chronic granulomatous disease followed for 21 years by a single
hospital in Japan. Eur J Pediatr 2008;167:1389–94.
28. Mouy R, Fischer A, Vilmer E, et al. Incidence, severity and prevention of infections
in chronic granulomatous disease. J Pediatr 1989;114:555–60.
29. Greenberg DE, Goldberg JB, Stock F, et al. Recurrent Burkholderia infection in
patients with chronic granulomatous disease: 11-year experience at a large
referral center. Clin Infect Dis 2009;48(11):1577–9.
Chronic Granulomatous Disease 9730. Ross JP, Holland SM, Gill VJ, et al. Severe Burkholderia (Pseudomonas) gladioli
infection in chronic granulomatous disease: report of two successfully treated
cases. Clin Infect Dis 1995;21:1291–3.
31. Sirinavin S, Techasaensiri C, Benjaponpitak S, et al. Invasive Chromobacterium
violaceum infection in children: case report and review. Pediatr Infect Dis J
2005;24:559–61.
32. Mailman TL, Schmidt MH. Francisella philomiragia adenitis and pulmonary
nodules in a child with chronic granulomatous disease. Can J Infect Dis Med
Microbiol 2005;16:245–8.
33. Greenberg DE, Shoffner AR, Zelazny AM, et al. Recurrent Granulibacter bethes-
densis infections and chronic granulomatous disease. Emerg Infect Dis 2010;
16(9):1341–8.
34. Greenberg DE, Shoffner AR, Marshall-Batty KR, et al. Serologic reactivity to
the emerging pathogen granulibacter bethesdensis. J Infect Dis 2012;206:
943–51.
35. Falcone EL, Holland SM. Invasive fungal infection in chronic granulomatous
disease: insights into pathogenesis and management. Curr Opin Infect Dis
2012;25:658–69.
36. Vinh DC, Freeman AF, Shea YR, et al. Mucormycosis in chronic granulomatous
disease: association with iatrogenic immunosuppression. J Allergy Clin Immunol
2009;123(6):1411–3.
37. Sugui JA, Vinh DC, Nardone G, et al. Neosartorya udagawae (Aspergillus udaga-
wae), an emerging agent of aspergillosis: how different is it from aspergillus fumi-
gatus? J Clin Microbiol 2010;48(1):220–8.
38. Morgenstern DE, Gifford MA, Li LL, et al. Absence of respiratory burst in X-linked
chronic granulomatous disease mice leads to abnormalities in both host defense
and inflammatory response to Aspergillus fumigatus. J Exp Med 1997;185:
207–18.
39. Siddiqui S, Anderson VL, Hilligoss DM, et al. Fulminant mulch pneumonitis: an
emergency presentation of chronic granulomatous disease. Clin Infect Dis
2007;45:673–81.
40. Marciano BE, Rosenzweig SD, Kleiner DE, et al. Gastrointestinal involvement in
chronic granulomatous disease. Pediatrics 2004;114:462–8.
41. Marks DJ, Miyagi K, Rahman FZ, et al. Inflammatory bowel disease in CGD repro-
duces the clinicopathological features of Crohn’s disease. Am J Gastroenterol
2009;104:117–24.
42. Soncini E, Slatter MA, Jones LB, et al. Unrelated donor and HLA-identical sibling
haematopoietic stem cell transplantation cure chronic granulomatous disease
with good long-term outcome and growth. Br J Haematol 2009;145:73–83.
43. Uzel G, Orange JS, Poliak N, et al. Complications of tumor necrosis factor-a
blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 2010;
51(12):1429–34.
44. Hussain N, Feld JJ, Kleiner DE, et al. Hepatic abnormalities in patients with
chronic granulomatous disease. Hepatology 2007;45:675–83.
45. Feld JJ, Hussain N, Wright EC, et al. Hepatic involvement and portal hypertension
predict mortality in chronic granulomatous disease. Gastroenterology 2008;134:
1917–26.
46. Walther MM, Malech HL, Berman A, et al. The urologic manifestations of chronic
granulomatous disease. J Urol 1992;147:1314–8.
47. Barese CN, Podesta´ M, Litvak E, et al. Recurrent eosinophilic cystitis in a child
with chronic granulomatous disease. J Pediatr Hematol Oncol 2004;26:209–12.
Holland9848. Hauck F, Heine S, Beier R, et al. Chronic granulomatous disease (CGD)
mimicking neoplasms: a suspected mediastinal teratoma unmasking as thymic
granulomas due to X-linked CGD, and 2 related cases. J Pediatr Hematol Oncol
2008;30:877–80.
49. Elloumi HZ, Holland SM. Diagnostic assays for chronic granulomatous disease
and other neutrophil disorders. Methods Mol Biol 2007;412:505–23.
50. Mauch L, Lun A, O’Gorman MR, et al. Chronic granulomatous disease (CGD) and
complete myeloperoxidase deficiency both yield strongly reduced dihydrorhod-
amine 123 test signals but can be easily discerned in routine testing for CGD.
Clin Chem 2007;53:890–6.
51. Ferguson PJ, Lokuta MA, El-Shanti HI, et al. Neutrophil dysfunction in a family
with a SAPHO syndrome-like phenotype. Arthritis Rheum 2008;58:3264–9.
52. Roos D, van Zwieten R, Wijnen JT, et al. Molecular basis and enzymatic proper-
ties of glucose-6-phosphate dehydrogenase volendam, leading to chronic
nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility
to infections. Blood 1999;94:2955–62.
53. Ro¨sen-Wolff A, Soldan W, Heyne K, et al. Increased susceptibility of a carrier of
X-linked chronic granulomatous disease (CGD) to Aspergillus fumigatus infection
associated with age-related skewing of lyonization. Ann Hematol 2001;80:113–5.
54. Brandrup F, Koch C, Petri M, et al. Discoid lupus erythematosus-like lesions and
stomatitis in female carriers of X-linked chronic granulomatous disease. Br J
Dermatol 1981;104:495–505.
55. Kragballe K, Borregaard N, Brandrup F, et al. Relation of monocyte and neutro-
phil oxidative metabolism to skin and oral lesions in carriers of chronic granulo-
matous disease. Clin Exp Immunol 1981;43:390–8.
56. Rupec RA, Petropoulou T, Belohradsky BH, et al. Lupus erythematosus tumidus
and chronic discoid lupus erythematosus in carriers of X-linked chronic granulo-
matous disease. Eur J Dermatol 2000;10:184–9.
57. Margolis DM, Melnick DA, Alling DW, et al. Trimethoprim-sulfamethoxazole
prophylaxis in the management of chronic granulomatous disease. J Infect Dis
1990;162:723–6.
58. International Chronic Granulomatous Disease Cooperative Study Group.
A controlled trial of interferon gamma to prevent infection in chronic granuloma-
tous disease. N Engl J Med 1991;324:509–16.
59. Rex JH, Bennett JE, Gallin JI, et al. In vivo interferon-gamma therapy augments
the in vitro ability of chronic granulomatous disease neutrophils to damage Asper-
gillus hyphae. J Infect Dis 1991;163:849–52.
60. Jackson SH, Miller GF, Segal BH, et al. IFN-gamma is effective in reducing infec-
tions in the mouse model of chronic granulomatous disease (CGD). J Interferon
Cytokine Res 2001;21:567–73.
61. Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic granulomatous
disease with myeloablative conditioning and an unmodified hemopoietic
allograft: a survey of the European experience, 1985–2000. Blood 2002;100:
4344–50.
62. Kang EM, Marciano BE, DeRavin S, et al. Chronic granulomatous disease: over-
view and hematopoietic stem cell transplantation. J Allergy Clin Immunol 2011;
127(6):1319–26.
63. OzsahinH,vonPlantaM,Muller I, et al.Successful treatmentof invasiveaspergillosis
in chronic granulomatous disease by bone marrow transplantation, granulocyte
colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B.
Blood 1998;92:2719–24.
Chronic Granulomatous Disease 9964. Horwitz ME, Barrett AJ, Brown MR, et al. Treatment of chronic granulomatous
disease with nonmyeloablative conditioning and T-cell-depleted hematopoietic
allograft. N Engl J Med 2001;344:881–8.
65. Kang EM, Malech HL. Gene therapy for chronic granulomatous disease. Meth
Enzymol 2012;507:125–54.
66. Kono H, Rusyn I, Yin M, et al. NADPH oxidase-derived free radicals are key
oxidants in alcohol-induced liver disease. J Clin Invest 2000;106:867–72.
67. Rusyn I, Kadiiska MB, Dikalova A, et al. Phthalates rapidly increase production of
reactive oxygen species in vivo: role of Kupffer cells. Mol Pharmacol 2001;59:
744–50.
68. Barry-Lane PA, Patterson C, van der Merwe M, et al. p47phox is required for
atherosclerotic lesion progression in ApoE (-/-) mice. J Clin Invest 2001;108:
1513–22.
69. Walder CE, Green SP, Darbonne WC, et al. Ischemic stroke injury is reduced in
mice lacking a functional NADPH oxidase. Stroke 1997;28:2252–8.
70. Kishida KT, Hoeffer CA, Hu D, et al. Synaptic plasticity deficits and mild memory
impairments in mouse models of chronic granulomatous disease. Mol Cell Biol
2006;26:5908–20.
71. Pao M, Wiggs EA, Anastacio MM, et al. Cognitive function in patients with chronic
granulomatous disease: a preliminary report. Psychosomatics 2004;45:230–4.
